pasireotide
Showing 1 - 25 of 80
Post-Bariatric Hypoglycemia Trial (Pasireotide Diaspartate)
Not yet recruiting
- Post-Bariatric Hypoglycemia
- Pasireotide Diaspartate
- (no location specified)
Jul 7, 2023
Gastro-enteropancreatic Neuroendocrine Tumor Trial (Pasireotide, Diazoxide)
Withdrawn
- Gastro-enteropancreatic Neuroendocrine Tumor
- Pasireotide
- Diazoxide
- (no location specified)
Feb 17, 2022
Enterostomy Trial in France (Pasireotide, Placebo)
Completed
- Enterostomy
- Pasireotide
- Placebo
-
Amiens, France
- +13 more
Mar 23, 2022
Neuroendocrine Tumors, Carcinoid Tumors Trial in Stanford, Tampa (Pasireotide Long Acting Release (LAR))
Active, not recruiting
- Neuroendocrine Tumors
- Carcinoid Tumors
- Pasireotide Long Acting Release (LAR)
-
Stanford, California
- +1 more
Jan 11, 2022
Hematological Malignancies Trial in Boston, Durham (Pasireotide)
Completed
- Hematological Malignancies
- Pasireotide
-
Boston, Massachusetts
- +1 more
Oct 19, 2021
Congenital Hyperinsulinism, Insulinoma, Hyperinsulinism Trial (Pasireotide 0.6Mg Solution for Injection, Saline Solution)
Withdrawn
- Congenital Hyperinsulinism
- +2 more
- Pasireotide 0.6Mg Solution for Injection
- Saline Solution
- (no location specified)
May 12, 2021
Pituitary Tumor, ACTH-producing Pituitary Tumour Trial in New York (Pasireotide LAR)
Terminated
- Pituitary Tumor
- ACTH-producing Pituitary Tumour
- Pasireotide LAR
-
New York, New YorkNeuroendocrine Unit and Pituitary Center, Columbia University
Mar 31, 2021
Cushing's Disease, Acromegaly, Neuroendocrine Tumors Trial in Worldwide (Pasireotide, Cabergoline)
Active, not recruiting
- Cushing's Disease
- +8 more
- Pasireotide
- Cabergoline
-
La Jolla, California
- +93 more
May 19, 2022
Peritoneal Carcinomatosis Trial in Villejuif (Pasireotide 0.9 MG/ML, Saline water)
Recruiting
- Peritoneal Carcinomatosis
- Pasireotide 0.9 MG/ML
- Saline water
-
Villejuif, FranceGustave Roussy
Mar 29, 2021
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer Trial in Detroit (docetaxel,
Completed
- Adenocarcinoma of the Prostate
- +3 more
- docetaxel
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 2, 2021
Metastatic Melanoma and Merkel Cell Carcinoma Trial in Essen, Lausanne, Zuerich (Pasireotide sub-cutaneous formulation,
Completed
- Metastatic Melanoma and Merkel Cell Carcinoma
- Pasireotide sub-cutaneous formulation
- Pasireotide lon acting release formulation
-
Essen, Germany
- +2 more
Dec 17, 2020
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System Trial in Germany (Pasireotide LAR
Completed
- Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
- Pasireotide LAR followed by Pasireotide LAR + Everolimus
- Everolimus followed by Pasireotide LAR + Everolimus
-
Bad Berka, Germany
- +3 more
Dec 17, 2020
Hepatic Cirrhosis, Alcoholism Trial in Worldwide (Pasireotide)
Completed
- Hepatic Cirrhosis
- Alcoholism
- Pasireotide
-
Richmond, Virginia
- +3 more
Dec 17, 2020
Neuroendocrine Tumors Trial in United States (Pasireotide LAR)
Completed
- Neuroendocrine Tumors
- Pasireotide LAR
-
Los Angeles, California
- +3 more
Dec 17, 2020
Pancreatic Fistula, Pancreatic Tumors Trial in Helsinki (Hydrocortisone, Pasireotide)
Active, not recruiting
- Pancreatic Fistula
- Pancreatic Neoplasms
- Hydrocortisone
- Pasireotide
-
Helsinki, FinlandHelsinki University Central Hospital
Aug 21, 2020
Neuroendocrine Carcinoma of the Lung and Thymus Trial in Worldwide (Pasireotide LAR, Everolimus, Pasireotide LAR and Everolimus
Completed
- Neuroendocrine Carcinoma of the Lung and Thymus
- Pasireotide LAR
- +2 more
-
Aarhus, Denmark
- +35 more
Mar 8, 2021
Carcinoid Tumor, Acromegaly Trial in Worldwide (Pasireotide)
Completed
- Carcinoid Tumor
- Acromegaly
- Pasireotide
-
Los Angeles, California
- +16 more
Dec 17, 2020
Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease Trial in Rochester (Pasireotide
Completed
- Somatostatin Analogs
- +3 more
- Pasireotide LAR
- Placebo
-
Rochester, MinnesotaMayo Clinic
Apr 30, 2020
Pasireotide on Postoperative Pancreatic Fistulas Following
Completed
- Surgical Complications
- Pasireotide 0.9 MG/ML
- (no location specified)
Feb 21, 2020